would like to highlight Zenosense, Inc.
). The company is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.
In the company’s news,
Zenosense has announced considerable progress in its MRSA/SA detector development. It has been determined that the prototype device achieved a sensibility detection rate over 95% on cultured headspace in a series of tests over a two week period in a clinical setting.
In other developments, the company’s general device technology development designed to detect the Methicillin-resistant Staphylococcus aureus “Super-Bug” (“MRSA”), non-resistant “Staph” (“SA”), is also moving forward in line with ZENO expectations.
Electronic improvements have resulted in printed circuit board prototyping that includes integration of a powerful solid state processor, a suitable, low power, piezo electric sampling pump, a capability to run up to four sensors of different technologies working in parallel on a tens of milliseconds sampling frequency, to include measuring and cleaning time and low power consumption enabling an extended operating time on battery power to cover at least one normal working shift when operating continuously.
A Volatile Organic Compound (“VOC”) capturing system, which enables the prototyped device to sample cultured headspace, has also been developed. The system includes an air injection system to enable the device to sample a negative vacuum, a suction process, data download and a cleaning cycle.
Pending developmental activity includes Quartz Crystal Microbalance sensor testing, sensitivity testing against VOC biomarkers, assessment of accuracy and repeatability, and a review of temperature sensitivity, humidity and gas interference factors.
Zenosense is a detection device development company with a mission to develop effective medical devices targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients. Its goal is to sell these products to hospitals and primary healthcare facilities. Devices currently under development are a device intended to detect the Methicillin-resistant Staphylococcus aureus (MRSA) and a device intended to detect Lung Cancer. Using a common Electronic Nose technology platform, the devices analyze Volatile Organic Compounds (VOCs) which are present in the exhaled breath of patients.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.